Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

30 Aug 2022

Cybin Doses First Patients in Phase 1/2a Depression trial

Cybin Inc....

By Microdose NewsDesk

Don’t Miss

29 Aug 2022

News You Might Have Missed: Aug 29th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Finance

27 Aug 2022

MindMed Completes 1-for-15 Reverse Share Split

MindMed Completes 1-for-15 Reverse Share Split....

By Microdose NewsDesk

Industry

26 Aug 2022

B.More Receives FDA Approval for Psilocybin Phase 2b Trial

B....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Don’t Miss

22 Aug 2022

News You Might Have Missed: Aug 22nd, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

19 Aug 2022

Hanging On or Closing Shop? Mydecine Announces $245K Financing

Today's announcement of a $245K in capital infusion could, perhaps, maybe, signal something hopeful for investors....

By Microdose NewsDesk

Industry

17 Aug 2022

Cybin Granted Schedule I DEA License for CYB003 Phase 1/2a Trial

Cybin and Clinilabs have been granted Schedule I DEA License for CYB003 Phase 1/2a clinical trial...

By Microdose NewsDesk

Industry

16 Aug 2022

Atai Reports Q2 2022 Financial Results & Business Update

Q2 results show that Atai has up to 487M to continue developing next-generation mental health treatment....

By Microdose NewsDesk

Don’t Miss

15 Aug 2022

News You Might Have Missed: Aug 15th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.